Aandeel APS APTOSE BIOSCIENCES INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Aptose Biosciences Inc.

Aandelen

APS

CA03835T3091

Beurs gesloten - Toronto S.E.
Andere beurzen
 21:59:35 24-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
1,66 CAD +0,61% Intraday-grafiek van Aptose Biosciences Inc. -5,14% -50,45%
26/03 Aptose Biosciences Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023 CI
26/03 Transcript : Aptose Biosciences Inc., Q4 2023 Earnings Call, Mar 26, 2024

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Certain Warrants of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
APTE BIOS : Aptose Corporate Presentation April 2024
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aptose Biosciences Up 3% After Hours as its 2023 Loss Widens on Higher R&D Spending
Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials"
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations with Excellent Safety Profile"
Aptose Biosciences Brief: Q4 Basic and diluted loss per Common Share US$7.58
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
North American Morning Briefing : Markets Steady -2-
North American Morning Briefing : Stock Futures -2-
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
Top Premarket Gainers
Aptose Biosciences Down 3% After Hours as it Raises US$13.7 Million in a Bought-Deal Offering, Private Placement
Aptose Biosciences Raises US$13.7 Million in a Bought-Deal Offering of Share Units and Concurrent Private Placement
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
Aptose Biosciences Brief: Announcing Closing of US$9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers APS
  4. Nieuws Aptose Biosciences Inc.
  5. Andere talen